Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 5
Submit an article Journal homepage
198
Views
14
CrossRef citations to date
0
Altmetric
Letter

Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma

Yasuhiro OkiDepartment of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Amanda CopelandDepartment of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Jorge RomagueraDepartment of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Luis FayadDepartment of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Michelle FanaleDepartment of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Silvana de Castro FariaDepartment of Diagnostic Imaging, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
L. Jeffrey MedeirosDepartment of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Percy IvyInvestigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, USA
&
Anas YounesDepartment of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
 show all
Pages 990-992 | Received 03 Aug 2011, Accepted 08 Oct 2011, Published online: 13 Mar 2012

References

  • Trepel J, Mollapour M, Giaccone G, . Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010;10:537–549.
  • Valbuena JR, Rassidakis GZ, Lin P, . Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. Mod Pathol 2005;18:1343–1349.
  • Goetz MP, Toft DO, Ames MM, . The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14:1169–1176.
  • Bonvini P, Dalla Rosa H, Vignes N, . Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res 2004;64:3256–3264.
  • Bonvini P, Gastaldi T, Falini B, . Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res 2002;62:1559–1566.
  • Georgakis GV, Li Y, Rassidakis GZ, . The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. Exp Hematol 2006;34: 1670–1679.
  • Georgakis GV, Li Y, Rassidakis GZ, . Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 2006;12:584–590.
  • Georgakis GV, Li Y, Younes A. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol 2006;135:68–71.
  • Grem JL, Morrison G, Guo XD, . Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885–1893.
  • Solit DB, Ivy SP, Kopil C, . Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007;13:1775–1782.
  • Banerji U, O'Donnell A, Scurr M, . Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23: 4152–4161.
  • Goetz MP, Toft D, Reid J, . Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078–1087.
  • Nowakowski GS, McCollum AK, Ames MM, . A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006;12:6087–6093.
  • Richardson PG, Mitsiades CS, Laubach JP, . Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol 2011;152:367–379.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.